David M. O'Malley MD

David M. O'Malley MD
Asst Professor - ClinicalCollege of Medicineomalley.46@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax:
  • Experimental Therapeutics

General Research Interest

Novel and innovative therapies for gynecologic cancers

Research Description

We continue to work toward improving improving outcomes in the treatment of gynecologic cancers by novel and innovative therapies. Our goal is to not only improve survival but also to improve quality of life. Multiple clinical trials involving new, experimental treatments are ongoing in addition to trials using standard therapies in unique schedules and applications to improve outcomes. Currently, we have trials involving novel therapies in ovarian (inluding primary peritoneal and fallopian tube), uterine (endometrial and sarcomas), cervical and vulvar cancer. We continue to study improved surgical techiques with safer, more exact and better recovery in robotic surgeries. Many of the above trials are supported by the NCI, GOG and investigator initated process.

Transinstitutional Work

Currently, we have multiple colloborations with many instutitons around the country within the Gynecologic Oncology Group (GOG). These colloborations have led to additional work in ovarian and endometrial malignancies with those and other cancer centers around the country.

Current Publications

  • Eisenhauer ELFeasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer-A Phase 1 Study.Int J Gynecol Cancer 3/19/2014
  • Hensley MLA phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study.Gynecol Oncol 3/1/2014
  • Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DEReducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care.Gynecol Oncol in press 10/4/2013
  • Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes MOvarian cancer, version 2.2013.J Natl Compr Canc Netw 11(10) 1199-209 10/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23(5) 833-8 6/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129(1) 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129(1) 103-6 4/1/2013
  • Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby GE 4th, Cohn DE, O'Malley D, Fowler JM, Holloway RWAnalysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.Gynecol Oncol 128(2) 309-15 2/1/2013
  • Secord AA, Geller MA, Broadwater G, Holloway R, Shuler K, Dao NY, Gehrig PA, O'Malley DM, Finkler N, Havrilesky LJA multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.Gynecol Oncol 128(1) 65-70 1/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128(1) 44-8 1/1/2013
  • McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler J, Cohn D, O'Malley DRecurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecol Oncol 127(2) 362-6 11/1/2012
  • Salani R, O'Malley DMHere it comes....the role of cost-effective analysis.Gynecol Oncol 127(2) 265-6 11/1/2012
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MAOvarian cancer, version 3.2012.J Natl Compr Canc Netw 10(11) 1339-49 11/1/2012
  • Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, Nagel CI, Cohn DE, Fader AN, Wallace AH, Rose P, Gehrig PAA multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.Gynecol Oncol 127(1) 22-6 10/1/2012
  • Backes FJ, Brudie LA, Farrell MR, Ahmad S, Finkler NJ, Bigsby GE, O'Malley D, Cohn DE, Holloway RW, Fowler JMShort- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging.Gynecol Oncol 125(3) 546-51 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu